A Phase 1 interventional study of BLU-263 and Azacitidine in Advanced Systemic Mastocytosis, sponsored by Blueprint Medicines Corporation. Terminated at 11 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Mastocytosis, Systemic by Sanofi — 4 open to participants now, 5 under way, 1 of them phase 3. Mastocytosis, Systemic · Sanofi.
Among the 10 studies in Mastocytosis, Systemic by Sanofi, this one is the only one that started in 2023, is one of 2 in phase 1, and was the 7th registered.
56 studies on the registry are indexed under Mastocytosis, Systemic; 16 are open to participants now.
Browse Mastocytosis, Systemic studies →4 of the 10 studies in Mastocytosis, Systemic by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Blueprint Medicines Corporation · Sites in United States
Ages 18+
Blueprint Medicines Corporation · Sites in Germany
Ages 18+
Blueprint Medicines Corporation · Sites in Belgium, Canada, France and 6 more countries
Blueprint Medicines Corporation · Sites in United States, Argentina, Australia and 22 more countries
Ages 18+
By country, each count listing its studies:
Of the 14 Mastocytosis, Systemic studies recruiting now, 12 (86%) set no upper age limit and 2 (14%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 1 · Phase 4 1
First in 2015; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 36 across 34 interventional studies indexed under Mastocytosis, Systemic.
Median enrollment 97 across the 6 interventional studies, 234 across the 4 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Blueprint Medicines Corporation, one of the names counted as Sanofi. Under that name alone:
Blueprint Medicines Corporation is the lead sponsor of 32 studies on the registry; 6 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 3 (21%) have results posted.
1 of the studies in Mastocytosis, Systemic by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03731260Blueprint Medicines Corporation(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | 2027-06-23 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Mastocytosis, Systemic by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate elenestinib (BLU-263) in participants with Advanced Systemic Mastocytosis (AdvSM), SM with an associated hematologic neoplasm (SM-AHN), and other hematologic malignancies. The main questions it aims to answer are:
The estimated study duration for each participant will be approximately 4 years: 2 years of treatment followed by 2 years of follow-up. Participants may be required to attend monthly visits for the first six months, followed by quarterly visits for the remainder of the study.
Systemic mastocytosis includes five major subtypes: Indolent SM (ISM), SM with an associated hematologic neoplasm (SM-AHN), aggressive SM (ASM), and MC leukemia (MCL). In 2016, the smoldering subtype of SM, a former provisional ISM subvariant, was designated as a distinct variant of SM by the World Health Organization (WHO). Aggressive SM, SM-AHN, and MCL together are referred to as Advanced SM (AdvSM).
Key Inclusion Criteria :
Arm 1 (Monotherapy): Participants must have one of the following AdvSM diagnoses, based on World Health Organization (WHO) diagnostic criteria.
Before enrollment, diagnosis of AdvSM must be confirmed based on Central Pathology Laboratory assessment of BM:
Key Exclusion Criteria:
Those participants maintained on a chronic dose of erythropoietin, whose is stable, and dose of erythropoietin has not been changed in the prior 28 days are allowed on study.
Arm 1 (Monotherapy):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with AdvSM (ASM, SM-AHN, or MCL) will receive BLU-263 monotherapy.
Drug: BLU-263
Participants with high risk and very high risk systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) of non-MC lineage will receive BLU-263 in combination with azacitidine.
Drug: BLU-263 · Drug: Azacitidine
BLU-263 Oral Tablets
Also known as: elenestinib
Azacitidine powder for suspension for intravenous infusion / subcutaneous injection
Dose Escalation: Number of Dose-limiting Toxicities (DLTs) (monotherapy only)
Monotherapy: The Recommended Dose (RD) will be primarily determined by the number of DLTs in the first 28 days of treatment with elenestinib (BLU-263) monotherapy.
Time frame: 28 Days
Dose Escalation: Number of DLTs (combination therapy only)
Combination therapy: The RD will be primarily determined by the number of DLTs (during 28 days starting from Day 15 of C1 or Day 15 of C2) with elenestinib (BLU-263) in combination with azacitidine.
Time frame: 28 Days
Dose Escalation and Expansion: Pure Pathological Response (PPR) Rate for SM in Selective KIT Inhibitor-naïve Participants (monotherapy only)
PPR Rate is defined as complete remission (resolution of palpable splenomegaly/hepatomegaly) (CR) + complete remission with partial recovery of peripheral blood counts (CRh) + partial remission (≥35% reduction in spleen volume) (PR)
Time frame: Up to approximately 4 years
Dose Escalation and Expansion: Number of Participants with Adverse Events (AEs)
Time frame: Up to approximately 4 years
Dose Escalation and Expansion: Number of Participants with Serious Adverse Events (SAEs)
Time frame: Up to approximately 4 years
Dose Escalation and Expansion: Overall Response Rate (ORR) for AdvSM using modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (IWG-MRT-ECNM) (monotherapy only)
ORR is defined as CR + CRh + PR + Clinical Improvement (CI)
Time frame: Up to approximately 4 years
Dose Escalation and Expansion: ORR for SM Using Modified IWG-MRT-ECNM (combination therapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: Maximum Plasma Concentration (Cmax) of BLU-263
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: Cmax of Azacitidine (combination therapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: Time to Maximum Concentration (Tmax) of BLU-263
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: Tmax of Azacitidine (combination therapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: Area Under the Curve From Time Zero to 24 Hours (AUC(0-24)) of BLU-263
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: AUC(0-24) of Azacitidine (combination therapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: Apparent Volume of Distribution (Vz/F) of BLU-263
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: Vz/F of Azacitidine (combination therapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: Terminal Elimination Half-life (t1/2) of BLU-263
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: t1/2 of Azacitidine (combination therapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: Apparent Oral Clearance (CL/F) of BLU-263
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: CL/F of Azacitidine (combination therapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: Accumulation Ratio of BLU-263
Time frame: Up to approximately 4 years
Dose Escalation and Dose Expansion: Accumulation Ratio of Azacitidine (combination therapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Expansion: Overall Survival (OS) (monotherapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Expansion: Time to Response (TtR) (monotherapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Expansion: Duration of Response (DOR) (monotherapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Expansion: Progression-Free Survival (PFS) (monotherapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Expansion: Proportion of Participants Pursuing Stem Cell Transplant (monotherapy only)
Time frame: Up to approximately 4 years
Dose Escalation and Expansion: PPR Rate for SM (combination therapy only)
Time frame: Up to approximately 4 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Jan 2025, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elenestinib
Blueprint Medicines Corporation →